NCCN Guidelines for Patients® | Esophageal Cancer - page 35

35
NCCN Guidelines for Patients
®
: Esophageal Cancer
Version 1.2013
Part 4: Overview of cancer treatments
Par t 1
Par t 2
Par t 3
Par t 4
Par t 5
Par t 6
Par t 7
Par t 8
Par t 9
Generic name
Brand name
(sold as)
Type of treatment
Capecitabine
Xeloda
®
Chemotherapy
Carboplatin
Chemotherapy
Cisplatin
Platinol
®
, Platinol
®
-AQ Chemotherapy
Docetaxel
Taxotere
®
Chemotherapy
Epirubicin
Ellence
®
Chemotherapy
Etoposide
Etopophos
®
Preservative Free
Chemotherapy
Fluorouracil (5-FU)
Chemotherapy
Irinotecan
Camptosar
®
Chemotherapy
Mitomycin
Chemotherapy
Oxaliplatin
Eloxatin
®
Chemotherapy
Paclitaxel
Taxol
®
Chemotherapy
Trastuzumab
Herceptin
®
Targeted therapy
4.5 Targeted therapy
Targeted therapy is the use of drugs to treat cancer. It stops the growth process
that is very specific to cancer cells. It is less likely to harm normal cells than
chemotherapy, which stops any cells in a growth phase.
Trastuzumab is a targeted therapy drug used to treat esophageal cancer.
Trastuzumab works by attaching to HER2—like a key into a lock—to stop cell
growth. More information about HER2 can be found in Part 3.1.
Table 2. Cancer drugs for esophageal cancer
Definitions:
DNA:
A chain of chemicals
inside cells that contains
coded instructions for
making and controlling cells
Acronyms:
HER2
=
human epidermal
growth factor receptor 2
1...,25,26,27,28,29,30,31,32,33,34 36,37,38,39,40,41,42,43,44,45,...100
Powered by FlippingBook